April 1st 2021
The ILLUMINATE-A trial of lumasiran in patients with primary hyperoxaluria type 1 supported the FDA approval of this drug.
September 12th 2012
August 29th 2012
Indications for prostate biopsy: Should all men have them?
June 1st 2006Brisbane, Australia-Decisions about when and how to perform prostate biopsy have become more complex in recent years, said Michael Jewett, MD, professor of surgery (urology), University of Toronto, in an address at the Urological Society of Australasia annual meeting here. The objective of biopsy should be to detect prostate cancer in men who will benefit from the information they yield.
Once-daily alpha-blocker curbs BPH symptoms
June 1st 2006Paris-Once-daily administration of a newer alpha-blocker appears to have a positive effect in the treatment of patients suffering from lower urinary tract symptoms and BPH compared with placebo, but comes up short in preventing acute urinary retention occurrence, according to Claus G. Roehrborn, MD, professor and chairman of the department of urology at the University of Texas Southwestern Medical Center, Dallas. Dr. Roehrborn presented the results of a 2-year study at the European Association of Urology annual congress here.
THC analog shows promise in painful bladder syndrome
June 1st 2006Atlanta-Intravesical administration of an agent that is chemically related to cannabis produces a positive response in laboratory rats and may be useful in patients with painful bladder syndrome/interstitial cystitis, investigators from the University of Pittsburgh reported at the AUA annual meeting.
Higher BMI is associated with more severe BPH
June 1st 2006Paris-Significant statistical correlations are seen between body mass index (BMI) and BPH symptoms, according to Claus G. Roehrborn, MD, who led a global 4-year treatment study evaluating the relationships of BMI and both measures of lower urinary tract symptoms (LUTS)/BPH severity and metabolic syndrome. Results of the study were presented at the European Association of Urology annual congress here.
Pre-TWOC alpha-blocker reduces urinary retention risk
June 1st 2006Paris-Trial without catheter (TWOC) after a median of 3 days' catheterization has become standard practice in France for patients with acute urinary retention associated with BPH, according to results of a prospective, cross-sectional survey assessing current AUR practice patterns. In addition, TWOC was significantly more successful in patients who received treatment with an alpha-blocker prior to a TWOC than it was in patients who did not receive an alpha-blocker, according to Francois Desgrandchamps, MD, who presented the study results at the European Association of Urology annual congress here.
Agent may curb bone loss in men with prostate cancer
June 1st 2006Atlanta-Men who are being treated with androgen deprivation therapy for progressive prostate cancer face a second, less-recognized risk: osteoporosis and bone fracture. An initial report from a 2-year trial shows that weekly treatment with the oral bisphosphonate alendronate (Fosamax) can halt and even reverse the bone loss associated with androgen deprivation therapy.
Two-drug regimen effective for premature ejaculation
June 1st 2006Paris-A combination regimen of tadalafil (Cialis) and slow-release fluoxetine (Prozac) can significantly prolong intravaginal ejaculation latency time (IELT) in patients suffering from premature ejaculation (PE), according to Brazilian researchers.
NAION incidence is not increased by PDE-5 inhibitor
June 1st 2006Atlanta-Results of an analysis based on approximately 52,000 patient-years of observation demonstrate that the incidence of nonarteritic anterior ischemic optic neuropathy (NAION) among men receiving sildenafil citrate (Viagra) is no higher than that occurring among men in the general population, Rachel E. Sobel, MPH, reported at the AUA annual meeting here.
Expulsive therapy: Two-drug combination found best
June 1st 2006Paris-Administration of corticosteroid therapy does not significantly increase the expulsion rate of distal ureteral stones. However, the synergistic effect of steroid therapy with concomitant administration of the alpha-blocker tamsulosin (Flomax) increases the effectiveness of tamsulosin, Italian researchers reported at the recent European Association of Urology annual congress here.
FDA approves new delivery system for IV antibiotic
June 1st 2006The FDA recently approved a new delivery system for the antibioticcefoxitin, which is indicated for the treatment of urinary tractinfections, gynecologic infections (eg, pelvic inflammatorydisease), and a number of other common infections.
Combination therapy improves both LUTS and ED
May 24th 2006Combining the alpha-blocker alfuzosin SR (Uroxatral) with thephosphodiesterase type-5 inhibitor sildenafil citrate (Viagra)appears to produce a greater therapeutic benefit in men with lowerurinary tract symptoms than either drug alone, researchers saidyesterday.
'Lemonade therapy' found effective for some stone patients
May 23rd 2006Mildly hypocitraturic patients unable to tolerate potassium citratetherapy experience significant increases in urinary citrate levelsand decreases in stone formation rate when they regularly ingest amixture of water and reconstituted lemon juice, researchers fromthe Duke University Medical Center, Durham, NC, reported hereyesterday.
Incidence of NAION not increased by PDE-5 inhibitor, data show
May 22nd 2006Results of an analysis based on approximately 52,000 patient-yearsof observation demonstrate that the incidence of nonarteriticanterior ischemic optic neuropathy (NAION) among men receivingsildenafil citrate (Viagra) is no higher than that occurring amongmen in the general population, Rachel E. Sobel, MPH, of Pfizer,reported yesterday.
Intravesical injection of THC analog efficacious for painfulbladders
May 21st 2006Intravesical administration of liposomal ajulemic acid (IP-751)produces a positive response in laboratory animals and may beuseful in patients with painful bladder syndrome or interstitialcystitis, say investigators from the University of Pittsburgh.IP-751 is an analog of tetrahydrocannabinol (THC)-11-oic acid,which in turn is a metabolite of THC, the main psychotropic elementof cannabis.
Botulinum toxin 'dramatically' improves OAB symptoms
May 15th 2006Paris-Botulinum toxin A (Botox) proves to be a safe,effective treatment modality in combating overactive bladdersymptoms in patients with idiopathic detrusor overactivity, Britishresearchers reported at the European Association of Urology annualcongress here.
Drug therapy rarely warranted in incontinent children
May 15th 2006Clearwater Beach, FL-Treating incontinence in children withsystemic medications should be considered a last resort, andalthough several products are available for treatment ofincontinence in adults, there have been few studies in children.
PDE-5 inhibitor safe, effective in hypertensive men
May 15th 2006Munich, Germany-The phosphodiesterase type-5 inhibitorvardenafil hydrochloride (Levitra) is a safe and effective optionin the treatment of erectile dysfunction in men being treated withcommon medications for hypertension, researchers report in a recentstudy published in the Journal of Sexual Medicine (2005; 2:856-64).Both hypertension and the drugs used to treat it have been known toadversely affect erectile function.
Large-scale BPH studies: Data are forthcoming
May 15th 2006The major discussions of advances in understanding and treating BPHmay take place in the hallways rather than in the official meetingrooms during this month's AUA annual meeting, Claus G. Roehrborn,MD, professor and chairman of the department of urology at theUniversity of Texas Southwestern Medical Center, Dallas, toldUrology Times.